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Edited by Gianni CesareniAbstract Amyloid-b peptide (Ab), the major constituent of se-
nile plaques in the Alzheimer’s disease (AD) brain, is the main
source of oxidative stress leading to neurodegeneration. The
methionine residue in this peptide is reported to be responsible
for neurotoxicity. Structurally similar substitution with methio-
nine 35 replaced by cysteine in Ab40 was synthesized, and this re-
sult in enhanced b-sheet structures according to both circular
dichroism (CD) spectra and b-ﬁbril speciﬁc ﬂuorescence assay
but attenuated cytotoxicity whether in the presence of copper
or not. These ﬁndings may provide further evidence on disclosing
the connection between amyloid b-aggregation and Ab-induced
neurotoxicity.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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A great deal of evidence suggests that amyloid-b peptide
(Ab) plays a causal role in the development of Alzheimer’s dis-
ease (AD) pathology, emerging from a variety of genetic, path-
ological, and biochemical studies [1,2]. Ab is a proteolytic
product derived from the larger amyloid precursor protein
(APP), resulting in the production of Ab peptides of varying
length: a 40-amino acid Ab peptide (Ab40) and a 42-amino acid
Ab peptide (Ab42) are the two species of most interest, of
which Ab40 is the major species [3]. Ab has been shown to in-
duce protein oxidation, lipid peroxidation, and reactive oxygen
species (ROS) formation in AD brain [4,5]. The binding be-
tween Ab and metals such as copper and zinc ions accelerates
b-aggregation and generates reactive oxygen species (ROS),
which in turn accelerates oxidative damage to other proteins
[6–8].
Among the proposed mechanisms involving Ab-induced oxi-
dative stress, Methionine 35 is thought to be a critical residueAbbreviations: AD, Alzheimer’s disease; Ab, amyloid-b peptide; APP,
amyloid precursor protein; ROS, reactive oxygen species; CD, circular
dichroism; HFIP, 1,1,1,3,3,3-hexaﬂuoro-2-propanol; WT, wide type;
ThT, thioﬂavin T; OD, optical density; MTT, 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide; DMSO, dimethyl sulfoxide
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doi:10.1016/j.febslet.2007.02.038[5,9,10], since it is the most susceptible residue in Ab peptide to
oxidation, especially under conditions of oxidative stress [11].
Ab peptides with Met 35 substituted by either norleucine or
cysteine are reported to be non-toxic and unable to induce oxi-
dative stress responses in cells [5]. The substitution of Met 35
in Ab(25–35) with Nle, Lys, Leu, and Tyr inhibits aggregation
and neurotoxicity of the peptide [7]. It is also reported that
Ab(1–28) does not induce oxidative stress or neurotoxicity in
the absence of methionine [12]. Oxidation of Met 35 in
Ab(1–40) hinders a conformational transition from random
coil to b-sheet and reduces the propensity of the peptide to
aggregate to form ﬁbrils [13]. The chemistry of Met in
Ab(25–35) is very diﬀerent than that of Ab(1–42) for the C-ter-
minal nature of Met in Ab(25–35), though both species end up
with a sulfuranyl free radical, but by diﬀerent mechanisms [14].
Ab(25–34) that lacks terminal methionine is nontoxic, suggest-
ing a key role of methionine leads to oxidative stress and
neurotoxicity [7].
Numerous studies have focused on the structure, aggregate
properties [15,16] and ﬁbril formation [17,18], and neurotox-
icity [19] of Ab peptides and their roles in AD. However, the
link between b-aggregation and neurotoxicity is still in dispute,
since it is diﬃcult to deﬁne whether these ﬁbrillar deposits are
the byproducts of neurodegeneration or precede the degenera-
tive process [5]. The b-amyloid cascade hypothesis states that
excessive aggregation of Ab is of importance in the pathogen-
esis of AD [2]. Mclean et al. [20] reported a negative correla-
tion between the density of deposits and the severity of the
disease, while soluble Ab and synaptic damage and cognitive
impairment were in good correlativity. Due to the importance
of Met 35 in oxidative stress and its possible role as an electron
donor for the reduction of Ab-bound transitional metals [21],
we use a synthetic Ab(1–40)M35C to test its aggregate and
neurotoxic properties in the presence of copper or not. Our re-
sults show that mutation of methionine to cysteine signiﬁcantly
enhances the bﬁbril components but impedes the cytotoxicity
with practically unchanged total aggregation. These data sup-
port for a negative correlation between the density of bﬁbril
and the severity of the disease.2. Materials and methods
2.1. Chemical reagents and materials
All cell culture reagents were obtained from Invitrogen (Carlsbad,
CA, USA) unless otherwise stated. 1,1,1,3,3,3-hexaﬂuoro-2-propanol
(HFIP), thioﬂavin T (ThT), dimethyl sulfoxide (DMSO), 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) andblished by Elsevier B.V. All rights reserved.
Fig. 1. Synthesized Ab(1–40)M35C with a cysteine substitution at
position 35.
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Louis, MO, USA). Other chemical reagents including CuCl2 Æ 2H2O,
L-glycine were obtained from Beijing Chemical Industry (Beijing,
China). Prior to use all buﬀers and stock solutions of copper ions were
ﬁltered through a 0.22-lm ﬁlter (Millipore, Cork, Ireland) to remove
any particulate matter.2.2. Peptide preparation
Ab(1–40)M35C (35Ab40) (Fig. 1) was synthesized by employing solid
phase Fmoc chemistry and produced by Biosynthesis Biotech Co. Ltd.
(Beijing, China). After removal from the resin and de-protection, the
sample was puriﬁed and characterized by reverse phase HPLC using
UV/Vis detection.
The lyophilized peptide was initially dissolved in HFIP to a ﬁnal
concentration of 1 mg/ml, shaken for 2 h at 4 C to entirely dissolve
the peptide, then sonicated for 1 min to remove any preformed struc-
tures [22]. The stock solution was aliquoted into siliconized tubes and
stored at 20 C. Prior to each experiment, the stock solution was
spin-vacuumed using Integrated Speed-Vac System (Thermo Savant)
then further diluted either with serum free neurobasal medium or
Tris-buﬀered solutions to a desired concentration. For cortical cultures
treated with Ab-Cu2+ mixtures, Cu2+ was present as a solution of one
part CuCl2 to six parts glycine [26].2.3. Circular dichroism measurements
Circular dichroism (CD) spectra were recorded at 25 C using a Jas-
co (Tokyo, Japan) 810 spectrometer. Brieﬂy, the peptide was dissolved
in HFIP and spin-vacuumed, then dissolved in 20 mM Tris–HCl (pH
7.4) with or without diﬀerent concentration of Cu2+, and the ﬁnal con-
centration of Ab in each sample was 50 lM. Next, each test sample
was added into a 1-mm path length cell (Hellma) and scanned. All
CD measurements were carried out using the following parameters:
2-nm bandwidth, 20 nm/min run speed, 0.5-nm step size, and 2-s re-
sponse time. Background values for each test were subtracted from
the corresponding CDs of each sample prior to the calculation of
CD values. Direct CD measurements (h, in mdeg) were converted to
molar ellipticity, [h] (deg cm2 mol1) using the formula [h] = h/
10 · c · l, where c represent the molar concentration and l the path
length (cm).2.4. Fluorescence spectroscopy (ThT assay)
The degree of b-aggregation is determined by thioﬂavin T (ThT) that
speciﬁcally binds to ﬁbrous structures [8,23]. First, WT Ab or 35Ab40
stock solution was diluted with 20 mM Tris–HCl in the presence of
copper or not, to a concentration of peptide at 10 lM. ThT was then
added to each test sample to a ﬁnal concentration of 10 lM. Each sam-
ple was prepared in 96-well Black Cliniplate (Corning) and shaken for
10 s prior to each measurement. Measurements were carried out every
20 min.
The relative degree of b-aggregation was determined in terms of
ﬂuorescence intensity, which was measured at 37 C using a Varioskan
multimode microplate spectrophotometer (Thermo) under kinetic ﬂuo-
rometric measurement mode. Measurements were performed at the
excitation and emission wavelength of 450 and 485 nm respectively,
which resulted in the optimum detection of amyloid ﬁbrils [24]. To ac-
count for background ﬂuorescence, the ﬂuorescence intensity mea-
sured from each control solution without Ab peptides was
subtracted from that of each solution containing Ab.2.5. Primary neuronal cultures
Cortical neuronal cultures were performed as described previously
[25–27] with some modiﬁcations. Brieﬂy, embryonic day 17 Sprague–
Dawley rat cortices were dissected free of meninges and cut into 1–
2 mm3 tissues, then dissociated in 0.125% (w/v) trypsin in Krebs buﬀer.
Cells were triturated using a ﬁlter-plugged ﬁne pipette tip, pelleted,
resuspended in plating medium (MEM with 10% FBS and 10% HS).
After 2 h the plating medium was replaced with fresh neurobasal med-
ium plus 2% B27 supplements, 1% penicillin–streptomycin, and
0.5 mM L-glutamine. This method resulted in cultures highly enriched
for neurons (>95% purity) as determined by immunostaining (data not
shown).
The neuronal cells were allowed to mature for 5 d in culture before
commencing treatment using freshly prepared serum free neurobasal
medium plus B27 supplements minus antioxidants [25,26]. Samples
were freshly prepared at Cu2+:peptide molar ratios of 0:1 and 1:1
respectively, and coincubated at 25 C for 15 min, then the mixtures
were added to neurons for 96 h [26].
2.6. Cell viability assay
The toxicity of variant Ab peptides with or without Cu2+ on cell cul-
tures was assessed quantitatively using MTT reduction assay [28,29].
Solutions containing Ab alone or Ab together with Cu2+ were pre-
pared as above. Brieﬂy, the medium was replaced with neurobasal
medium plus B27 lacking antioxidants (250 ll), and 10% MTT (v/v)
was added to each well in a 48-well plate then incubated for 4 h at
37 C with 5% CO2. Upon removal of the medium, DMSO was added
to solubilize the MTT formazan. Absorbance was determined using a
lQuant MQX200 reader (Bio-Tek) at a wavelength of 570 nm and a
reference wavelength of 630 nm, and background readings of MTT
incubated in cell-free medium were subtracted from each value before
calculations. The data were normalized and calculated as a percentage
of untreated control values prior to analysis.3. Results
AD is characterized by a change in the main chain confor-
mation of Ab. Therefore, to determine the structure change
of peptides induced upon copper binding is of special interest.
CD spectra in the far UV region (190–240 nm) were recorded
to investigate the structuring of peptides upon Cu2+ addition.
The spectral curve of WT Ab40 in the absence of Cu
2+ exhib-
ited a minimum ellipticity at around 200 nm (Fig. 2a), suggest-
ing the secondary structure of Ab under these conditions is
mainly random coil structure [30]. As Cu2+ was titrated in,
the spectral curve slightly shifted to 198 nm, and the negative
signal reduced in intensity, indicating either the peptide is
becoming slighter more orderly, or that the change observed
could be due to sample precipitation. To investigate if the eﬀect
was resulted from precipitation of Ab and thus loss of CD sig-
nal, varying concentration of peptide were used. The loss of
signal was deﬁnitely dependent on the concentration of peptide
(data not shown), suggesting the eﬀect is due to precipitation
upon addition of copper. Of all the spectra detected, hardly
any signiﬁcant change in structuring of Ab40 could be observed
after the addition of 1 mol equivalent of Cu2+.
In the contrast, the spectral curve of 35Ab40 alone displayed a
minimum at around 213 nm (Fig. 2b), which is a characteristic
of b-sheet structure.With the addition of gradient concentration
of Cu2+, these curves had slightly negative ellipticities around
220 nm and positive ellipticities around 203 nm. This type of
curve was especially conspicuous when one mol equivalent
Cu2+ was contained in the sample. These curves most resemble
the type II b-turn conformation, although it is insuﬃcient to
make such a conclusion. However, the 35Ab40 spectral curve
with addition of copper suggests a non-b-sheet conformation.
Fig. 2. UV region CD spectra of various Ab peptides titrated with
Cu2+. Molar ellipticity of WT Ab40 (a) and
35Ab40 (b) was recorded in
the UV region (190–240 nm) with increasing mol equivalent of Cu2+.
Variant Ab peptide was diluted using 20 mM Tris–HCl (pH 7.4) to a
ﬁnal concentration of 50 lM in each sample. The data obtained
represent for the average of 10 runs.
Fig. 3. Kinetic measurements of b-aggregation resulted from incuba-
tion of WT Ab40 (a) and
35Ab40 (b) with or without addition of Cu
2+.
Each sample containing 10 lM Ab was incubated with 10 lM ThT in
the absence (d) or presence (s) of 10 lM copper. Experiments were
carried out at pH 7.4. Each point represents the average of six
independent experiments. Error bars represent S.E. values.
X.-L. Dai et al. / FEBS Letters 581 (2007) 1269–1274 1271To further validate the results obtained from CD spectra, we
determined the inﬂuence of Cu2+ on b-sheet structure and total
aggregation in Ab using the same peptide solutions. By using
ThT that specially binds to ﬁbrous structures, we assessed
the time course of b-aggregation formed by WT Ab40 and
35Ab40 in the absence or presence of Cu
2+. Since CD spectra
of various peptides exhibited deﬁnite changes when one mol
equivalent Cu2+ was present, we adopted a Cu2+:peptide molar
ratio of 1:1 here and in the following experiments unless other-
wise indicated.
It is interesting to note that 35Ab40 produced much higher
ﬂuorescence signal than WT Ab40, this increase in signal may
be due to secondary structure changes of modiﬁed Ab
(35Ab40) leading to a greater binding capacity for ThT or an
increase in the total amount of aggregation. In the absence
of copper, WT Ab40 showed higher ﬂuorescence signal suggest-
ing much content of b-aggregation (Fig. 3a), while it is the con-
trary case to 35Ab40. A decrease in ThT intensity was detected
during the whole incubation course, and additional ThT was
added to determine if the decreased ThT signal was due to deg-
radation of ﬂuorescent dye or structural alteration. As ex-
pected, no markedly increased signal (data not shown) couldbe observed in the presence of excessive ThT, suggesting a loss
of b-aggregation during the time course. Copper induced shifts
in the aggregation proﬁle from b-aggregation to amorphous
aggregates were evident for WT Ab40, whereas more b-aggre-
gation reserved as for 35Ab40 in the presence of copper
(Fig. 3b). Samples containing WT Ab40 showed lower ThT
ﬂuorescence intensity compared with 35Ab40, whether in the
presence of copper or not.
OD214 assay was adopted to assess total aggregation of WT
Ab40 and
35Ab40 under the same conditions with ThT assay,
whether in the presence or absence of copper respectively.
The results indicated that WT Ab40 or
35Ab40 contained simi-
lar amount of aggregates (data not shown), while a compara-
tively higher proportion of deposits when copper was present.
In order to determine if there is a direct correlation between
the cytotoxicity of Ab peptides and the peptides’ ability to
form amyloid material, WT Ab40 and
35Ab40 at Cu
2+:peptide
molar ratios of 0:1 and 1:1 was added to cortical neuronal cul-
tures to test for the neurotoxicity (Fig. 4). Only samples con-
taining WT Ab40 exhibited neurotoxicity at 5 lM, with the
Cu2+:peptide molar ratio of 1:1 the most toxic. Toxicity was
completely rescued with methionine substituted by cysteine
Fig. 4. Cytotoxicity of WT Ab40 and
35Ab40 at variant Cu
2+:peptide
molar ratios. Primary neuronal cells were grown at low density
(1.25 · 105 cells/cm2) for 5 d, then neuronal cells viability following
diﬀerent treatment was determined by measuring the inhibition of
MTT reduction. Cortical neurons were exposed to WT Ab40 or
35Ab40
at a ﬁnal concentration of 5 lM at Cu2+:peptide molar ratios of 0:1
(black bars) and 1:1 (grey bars) for 96 h in serum free media. Statistical
comparisons on groups were done using Student’s t-test. Error bars
represent S.E. values. * symbolize P < 0.01 versus control. At least
three samples were done/group, each experiment was carried out in
triplicate.
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therefore appears that conditions leading to the cytotoxicity
of Ab could be attributed to Met 35. Viability of neurons trea-
ted with copper alone was in close similarity with that left un-
treated.4. Discussion
After being secreted from APP, Ab peptide changes its solu-
ble state to form aggregates, ﬁnally deposits as senile plaques,
manifested as the main pathological hallmark of AD [1,2]. Se-
nile plaque cores contain abnormally high level of copper and
zinc ions [31], suggesting these metal ions may play a signiﬁ-
cant role in the formation and neurotoxicity of Ab ﬁbrils or
oligomers. Recently, direct evidence (from EPR and raman
microscopy spectroscopy) shows that Cu2+ is bound to Ab
via the histidine bridge within senile plaque cores [26,32].
It is reported that a key stage in the pathogenesis of Ab is a
structural alteration of the main-chain from the predominantly
random structure of soluble Ab to a b-sheet rich conformation
in senile plaques [33]. CD bands in the amide region (190–
240 nm) give information about the peptide bonds and second-
ary structure of a protein [34]. For this reason, the eﬀect of
copper ions on the main-chain conformation is of signiﬁcant
interest. Our CD data from metal-binding of WT Ab(1–40)
suggest that copper chelation does not induce a profound
structural transition or changes in the secondary structure
(Fig. 2a). Reduction of CD values in the far UV region can
be attributed to Cu2+-induce aggregation thus loss of signal.
Taken together with comparisons of variant spectral curves
of the peptide with Cu2+ titration, our data suggest that bind-
ing of the ﬁrst mol equivalent of Cu2+ appears to be suﬃcient
for the Ab-Cu2+ complex.Met-35 in the pathogenic activity of Ab has been suggested
that this residue is necessary for promoting neurotoxicity,
aggregation, and the generation of ROS [5,21]. Since metal
binding occurs near the N-terminus of Ab [26,32], methionine
residue could not be expected to have large eﬀects on the metal
binding activity. This was conﬁrmed by our CD spectra
(Fig. 2b) showing a distinct spectral curve with addition of
Cu2+, suggesting copper binding activity was unaﬀected
though methionine was replaced by cysteine. WT Ab40 is pre-
dominately random coil [24], whereas the mutant 35Ab40 alters
the secondary structure of this peptide resulting in a higher
proportion of b-sheet structure under the same case. More-
over, the addition of Cu2+ to 35Ab40 drives a structural transi-
tion to presumably b-turn structure, and the spectral curves
seem to change all along the copper titration (Fig. 2b), imply-
ing a dimensional alteration may occur on 35Ab40 structures
that aﬀect the binding capability for Cu2+. However, the addi-
tion of copper to WT Ab40 does not result in such a structural
transition, and b-sheet structures are not observed (Fig. 2a).
Signiﬁcantly, the lack of Met-35 does not change the metal
binding properties of Ab peptide, which is in agreement with
previous ﬁnding shows coordination of Cu2+ to Ab128 [35].
One controversy in the amyloid hypothesis is whether or not
Ab plaques are required for toxicity [17,22]. At least two var-
iant aggregation pathways formed for Ab: one leads to b-struc-
ture aggregate and the other to unstructured aggregate [17].
The b-structured aggregate is mainly composed of Ab peptides
that have b-sheet secondary structure, but the unstructured
aggregate lacks ordered structure, and its constituent peptides
are not tightly associated [36]. Results from the ThT and OD
assays lead us to hypothesize that, in addition to b-aggregate,
another type of aggregate is formed. The idea logically origins
from higher b-aggregation contents in AbM35C compared to
WT Ab40, but almost unaltered overall aggregation. With or
without addition of copper hardly exerts any inﬂuence on
the total aggregate proﬁle. Although CD spectroscopic pattern
may suggest that Cu2+ induce 35Ab40 to take b-turn conforma-
tion, more speciﬁc method such as NMR would be necessary
for the precise identiﬁcation [24]. However, the reduction of
ThT ﬂuorescence of WT Ab40 with addition of copper or not
during the time course (Fig. 3a), is contrary to the previous
studies which suggest enhanced ﬂuorescence intensity [24,37].
The reason for these discrepancies is not clear, although they
could be the result of several factors such as diﬀerences with
the handling of Ab (lot-to-lot variability) [38] or diﬀerences
in the solution conditions, such as pH, peptide concentrations,
temperature, agitation, time course and the type of peptide em-
ployed (Ab140 or Ab142). As for the ﬁnal ﬁbrous appearance,
WT Ab40 exhibits higher ﬂuorescence than that observed in the
presence of Cu2+ (Fig. 3a), which is contrast to b-aggregates
formed in sample containing 35Ab40 where Cu
2+-binding re-
sulted in more b-ﬁbrils upon the overall time course
(Fig. 3b). During the time course of bﬁbril degradation
in vitro, it appears that steady ﬂuorescence signal is displayed
from the time point of 1000 min.
Ab1–40 has been found in AD brains with high concentra-
tions, and this peptide is highly soluble and toxic [2,3]. The
synaptic damage and cognitive impairment associated with
AD correlates with the soluble forms of Ab, not the deposited
forms [20]. Additionally, the C. elegans model expressing
human Ab(1–42) has been used to show that protein oxidation
precedes the ﬁbrillar aggregation [39], supporting the role of
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oxidative stress and neurotoxic properties of the norleucine
derivative of Ab(1–42) but still produce ﬁbrils [9,40,41], also
foretell the results of our present study of AbM35C derivative.
The deleterious eﬀect of WT Ab40 on neuronal cells is remark-
able upon a time course of 96 h, even at a low concentration at
5 lM (see Fig. 4), and the toxic eﬀect is consistent with former
studies [24,25]. Moreover, we do observe a decrease of Cu2+-
induced b-aggregation in WT Ab40 and thus ﬁbrillogenesis,
resulting in enhanced cytotoxicity in primary neuronal cultures
quantitated by MTT assay compared to those containing WT
Ab40 alone. One explanation for this ﬁnding is that Ab-Cu
2+
compound is capable of promoting potentially toxic, pro-oxi-
dative reactions, resulting in the generation of ROS [6,42],
though the precise mechanism is unknown. As Ab binds
Cu2+ and reduces it to Cu+, methionine is oxidized to sulfoxide
[43], thus when Cu2+ is present, such involvement is a conse-
quence of the presence and properties of methionine. Since
the Cu2+-induced toxicity was partly rescued by catalase or
antioxidants [42,44], these studies provide further evidence
indicating that the enhanced toxicity involving Cu2+ supple-
mentation was mediated by ROS production.
The toxic species of Ab involving Met is likely the sulfuranyl
free radical on methionine, which initiates a chain reaction of
propagating free radical reactions involving abstraction of
hydrogen atoms from allylic carbons on acyl chains of the lipids,
when Ab as a small oligomer solubilizes in the lipid bilayer of
neuronal membranes [45]. Computational studies showed that
the sulfur-centered radical cation of methionine can lead to
the generation of a-carbon-centered radical on glycine 33, thus
producing hydrophobic species that can initiate peroxidation
in the lipid bilayer [46,47]. The basis of how Ab species exert
their toxic eﬀects in vivo is a complex and not yet fully under-
stood subject, although it appears that some form of peptide
assembly is an inevitable step [48,49]. Substitution ofmethionine
with cysteine residue, which converts a hydrophobic residue into
a more hydrophilic one, can markedly alter the properties of a
protein. For example, conformational transition from a-helix
to b-sheet structure can occur [50]. In the case of Ab40, the
replacement ofMet-35 for cysteine has been shown to attenuate
the neurotoxic property of the peptides [5]. Our results are con-
sistent with AbM35C markedly altering the structural and neu-
rotoxic properties of Ab [5,40], deﬁnitively show decreased
toxicity to neuronal cells in primary culture, whether in the pres-
ence of copper or not (Fig. 4). This ﬁnding coupled with former
studies usingmutant peptides has demonstrated a critical role of
methionine in the neurotoxic properties of Ab40 [5,7,10].
Due to the diﬀerences between the native peptide and the
methionine mutant peptide, including the contents of b-aggre-
gation, and the cytotoxicity of these peptides, it is possible that
non-bﬁbril species are the most likely candidates responsible
for the neuronal damage and cognitive impairment observed
in the AD brain. Our ﬁndings are consistent with the lack of
correlation between ﬁbrillar aggregates and oxidative stress
and neurotoxicity [39,41]. Furthermore, it has been suggested
that toxicity induced by Ab can be abolished by converting
the oligomeric form to the ﬁbrillar form [51]. In the present
study, the mutant peptide AbM35C provides us with a new re-
search tool with its abolished neurotoxicity compared with
wide type Ab40. Studies are currently in progress to further elu-
cidate the mechanism by which amyloid plaques are associated
with Ab-induced cytotoxicity [27,39]. In conclusion, we believethese results enlighten on mechanistic knowledge of ﬁbrilliza-
tion reactions [52] to provide a more profound understanding
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